Stay updated on LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.

Latest updates to the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page
- Check2 days agoChange DetectedThe study record for NCT04887259 shows termination of the LAVA-051 trial. The note states this decision was a business decision and not due to safety concerns, and that the study did not progress to Phase 2.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check31 days agoChange Detected- Added a government operating-status notice and current status pointers; updated version to v3.2.0. - Removed the specific condition 'B-cell chronic lymphocytic leukemia' and the older version tag v3.1.0.SummaryDifference4%

- Check38 days agoChange DetectedUpdate terminology from Plasma cell myeloma to Multiple myeloma and bump revision from v3.0.2 to v3.1.0.SummaryDifference0.2%

- Check53 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed. No changes to pricing, stock, or other core content.SummaryDifference0.2%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%

- Check67 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as resources related to various types of leukemia. Notably, several previous resources and location details have been removed.SummaryDifference10%

Stay in the know with updates to LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.